{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-056782","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.268058+00:00","generated_at":"2026-05-14T21:33:43.994217+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iovance Q1 revenue $71M (+45% YoY); guides FY26 $350-370M; endometrial cancer 40% cORR","bullets":["Total product revenue ~$71M in Q1 2026, up 45% YoY; U.S. Amtagvi revenue ~$60M, Proleukin ~$11M.","FY 2026 revenue guidance $350-$370M; Q2 2026 guidance $86-$88M.","Lifileucel in metastatic serous endometrial cancer: 40% confirmed ORR, 100% DCR in first 5 patients; FDA expedited path planned.","Cash ~$319M, expected to fund operations into 2028; R&D expenses down 12% vs Q4 2025.","UK MAA for lifileucel withdrawn for procedural reasons, will resubmit; EMA resubmission planned for 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-056782","json":"https://secwatch.observer/filing/0001104659-26-056782.json","markdown":"https://secwatch.observer/filing/0001104659-26-056782.md","text":"https://secwatch.observer/filing/0001104659-26-056782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/0001104659-26-056782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/tm2613648d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:33:43.994217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2fea2583f398b0e6f49d62d821a65fe3c0b678f3","claim":"IOVANCE BIOTHERAPEUTICS, INC. reported Full year 2026 results: revenue $350 million to $370 million. Guidance initiated.","evidence_excerpt":"Total product revenue guidance for 2Q26 is $86 million to $88 million and for FY26 is $350 million to $370 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/0001104659-26-056782-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full year 2026"},{"label":"Revenue","value":"$350 million to $370 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"515104e0d91167cb07da9287067c2c40e15bc7b0","claim":"IOVANCE BIOTHERAPEUTICS, INC. reported Second quarter 2026 results: revenue $86 million to $88 million. Guidance initiated.","evidence_excerpt":"Total product revenue guidance for 2Q26 is $86 million to $88 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/0001104659-26-056782-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Second quarter 2026"},{"label":"Revenue","value":"$86 million to $88 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"ea269a5eec289c64fd56c0c9c359f412516dba46","claim":"IOVANCE BIOTHERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: revenue ~$71 million.","evidence_excerpt":"and long-term value for patients and shareholders.” First Quarter 2026 Financial Highlights Continued Strength in Execution and Cost Discipline · Total product revenue of ~$71 million increased by ~45% over 1Q25, reflecting significant performance improvements over the prior annual maintenance period. o U.S. Amtagvi revenue was ~$60 million. o Global","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/0001104659-26-056782-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"~$71 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}